Related Experiment Video

Updated: Feb 1, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Palbociclib overcomes afatinib resistance in non-small cell lung cancer

Huijuan Nie1, Xiaoyan Zhou1, Du Shuzhang1

  • 1Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|December 16, 2018
PubMed

Insights

This study shows that combining Palbociclib with afatinib can overcome acquired resistance in non-small cell lung cancer (NSCLC) cells. This combination therapy reduces cancer cell survival and recurrence, offering a new strategy for treating resistant pulmonary malignancies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Afatinib, a second-generation tyrosine kinase inhibitor (TKI), is used for advanced/metastatic EGFR-mutant non-small cell lung cancer (NSCLC).
  • Acquired resistance limits the clinical efficacy of afatinib in NSCLC treatment.
  • CDK4/6 inhibitors are known to inhibit cell proliferation and induce differentiation and death in various cancer cells.

Purpose of the Study:

  • To investigate the efficacy of combining Palbociclib (a CDK4/6 inhibitor) with afatinib in reversing acquired resistance in NSCLC cells.
  • To evaluate the synergistic effects of this combination therapy on resistant NSCLC cell survival and tumor xenografts.

Main Methods:

  • In vitro studies assessing cell survival upon combination treatment.
  • In vivo xenograft models to evaluate the attenuation of resistance and tumor recurrence.

Main Results:

  • Combined Palbociclib and afatinib treatment demonstrated synergistic effects in reducing the survival of NSCLC cells with acquired resistance.
  • The combination therapy effectively attenuated resistance, leading to reduced recurrence of malignancies in xenograft models.

Conclusions:

  • The combination of Palbociclib and afatinib represents a promising and innovative strategy to overcome acquired resistance in non-small cell lung cancer.
  • This therapeutic approach holds potential for improving treatment outcomes in patients with resistant pulmonary malignancies.
Keywords:
AfatinibDrug resistanceNSCLC cellsPalbociclibRB

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

413

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
210
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.6K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
6.0K
Equivalent Resistance01:16

Equivalent Resistance

In circuit analysis, situations often arise where resistors are neither in series nor parallel configurations. To tackle such scenarios, three-terminal equivalent networks like the wye (Y) (Figure 1 (a)) or tee (T) and delta (Δ) (Figure 1 (b)) or pi (π) networks come into play. These networks offer versatile solutions and are frequently encountered in various applications, including three-phase electrical systems, electrical filters, and matching networks.
981